Finasteride Chemoprevention Might Be Cost-Effective in High-Risk Populations
May 2008
in “
Nature Clinical Practice Urology
”
TLDR Finasteride may be cost-effective for preventing prostate cancer in high-risk groups.
The study by Svatek and colleagues analyzed the cost-effectiveness of finasteride chemoprevention for prostate cancer, focusing on quality-of-life improvements. While the Prostate Cancer Prevention Trial indicated that finasteride reduced the 7-year prevalence of prostate cancer, previous research highlighted the high cost of widespread use, ranging from $578,400 to $1,107,000 per life-year saved, which exceeded the accepted cost-effectiveness threshold of $50,000 to $100,000. The new model-based analysis suggested that finasteride might be cost-effective in high-risk populations when considering the quality-of-life benefits associated with cancer prevention.